Evaluating The Clinicopathologic Characteristics and Survival Outcome of Breast Cancer Patients with Isolated Brain Metastases after Adjuvant Treatment or at Initial Diagnosis

Boruban C., Gulyer H., Altundag K., ARTAÇ M., Guler T., CENGİZ M.

EUROPEAN JOURNAL OF GENERAL MEDICINE, vol.9, no.4, pp.265-269, 2012 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 4
  • Publication Date: 2012
  • Doi Number: 10.29333/ejgm/82442
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.265-269
  • Hacettepe University Affiliated: Yes


CNS metastases usually appears late in the progression of metastatic breast cancer. Classical approach is evaluating and treating them when symptoms become evident. We evaluated the survival and described clinicopathologic characteristics of patients in whom the brain metastases after adjuvant treatment or at initial diagnosis are the first and the only side. Authors retrospectively evaluated about 3600 patients with breast cancer treated in two university hospitals. In those 31 patients with first and only metastases to brain and no other metastases were evaluated. ER, PR, cerbB2 status T, N stage, grade, adjuvant taxane, trastuzumab, hormonal treatment, trastuzumab and platine use after brain metastases didn't effect the survival. Surgery and WBRT may be more effective in cerbB2 negative patients, WBRT in cerbB2 positive ones. (p=0.06). The survival outcome may be better in pre and perimenouposal women. The mOS of pre and perimenopausal, postmenopausal women were 17.7 months and 10.3 months respectively (p=0.06) and lapatinib may affect the mOS of patients with isolated brain metastases. Some prognostic factor may help us to foresee which group may benefit more from which treatment modality. The need for studies with larger groups of patients is obvious.